Tirzepatide (Mounjaro): Indication: For once-weekly administration as an adjunct to diet and exercise to improve glycemic control for the treatment of adult patients with type 2 diabetes mellitus: Reimbursement Recommendation
Abstract
What is the reimbursement recommendation for mounjaro?: Canada’s Drug Agency (CDA-AMC) recommends that Mounjaro be reimbursed by public drug plans as an add-on to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus (T2DM) when combined with metformin, metformin and a sulfonylurea, or metformin and a sodium-glucose cotransporter-2 (SGLT2) inhibitor if certain conditions are met.
Why did cda-amc recommend reimbursement?: The Canadian Drug Expert Committee (CDEC) determined that Mounjaro demonstrates acceptable clinical value versus glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in adults with T2DM. This determination was enough for CDEC to recommend that tirzepatide be reimbursed. Given that tirzepatide is expected to be an alternative to GLP-1 RAs, such as semaglutide, acceptable clinical value refers to at least comparable value versus this group of drugs. Evidence from 3 phase III randomized controlled trials showed that Mounjaro 5 mg, 10 mg, and 15 mg reduced blood sugar levels in adults with T2DM receiving various background therapies compared to semaglutide 1 mg, insulin degludec, and insulin glargine; however, CDEC considered the results for Mounjaro 5 mg to be similar to semaglutide 1 mg in hemoglobin A1C reduction. Evidence from an additional phase III randomized controlled trial demonstrated that the highest tolerable dose of Mounjaro was just as effective as dulaglutide 1.5 mg in reducing major adverse cardiovascular…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.